Actively Recruiting
Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)
Led by University Hospital, Strasbourg, France · Updated on 2025-09-05
550
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
While the reduced hemorrhagic risk of radial access for percutaneous coronary intervention compared to femoral access is well-established, its main complication remains radial artery occlusion, which can occur in up to 30% of patients. Anticoagulation is the primary preventive measure recommended in clinical practice to reduce the risk of this complication, typically involving heparin injection during the procedure in most centers. However, data on the effect of the timing of heparin injection are limited. The investigators hypothesize that injection of heparin before sheath insertion may reduce the rate of radial artery occlusion compared with injection after sheath insertion.
CONDITIONS
Official Title
Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older undergoing percutaneous radial coronary intervention
- Affiliated to a social protection health insurance
- Able to understand the study objectives and risks and provide written informed consent
- Informed of the results of the preliminary medical examination
You will not qualify if you...
- Contraindication to heparin use such as history of heparin-induced thrombocytopenia
- Very high bleeding risk defined by recent bleeding (<6 months) of type 3 BARC classification
- Currently participating in another study or within an exclusion period
- Unable to understand or provide informed consent (emergency situation, comprehension difficulties)
- Under legal protection such as safeguard of justice, guardianship, or curatorship
- Pregnant or breastfeeding
- Taking anticoagulant treatments such as anti-vitamin K or direct oral anticoagulants (DOACs)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpitaux Universitaires de Strasbourg
Strasbourg, Bas-Rhin, France, 67091
Actively Recruiting
Research Team
P
Pr Patrick OHLMANN Pr Patrick OHLMANN, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here